Xanomeline Tartrate

6 trials 4 recruiting

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

4 Recruiting

0 Completed trials

1 Sponsors

14 Countries

Phase III

Phase III: 6

Indications tested

Dementia Alzheimer's type 5 Autism spectrum disorder 1 Schizophrenia 1

Sponsors using this IMP

Bristol-Myers Squibb Services Unlimited Company 6

All trials

6 total

Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending

2024-519994-20-00 Phase III 11 countries Bristol-Myers Squibb Services Unlimited Company
Phase 3 Evaluation of KarXT and KarXT+KarX-EC in Schizophrenia and Autism-Related Irritability in Youth, respectively. Pending

2025-524062-16-00 Phase III 1 country Bristol-Myers Squibb Services Unlimited Company
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520746-30-00 Phase III 8 countries Bristol-Myers Squibb Services Unlimited Company
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520612-34-00 Phase III 5 countries Bristol-Myers Squibb Services Unlimited Company
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520613-31-00 Phase III 6 countries Bristol-Myers Squibb Services Unlimited Company
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520747-32-00 Phase III 10 countries Bristol-Myers Squibb Services Unlimited Company

Showing 1–6 of 6 trials

← All drugs A–Z